Clinical trials: OPSCC
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04106362
- Testing
- Cetuximab, Cisplatin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
This phase I, open-label, single-arm trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efffcacy of intranasal WSK-IM05 vaccine combined with tislelizumab as neoadjuvant therapy in…
- Trial name
- NCT07565740
- Testing
- WSK-IM05 (4×10^10 vp), WSK-IM05 (8×10^10 vp), WSK-IM05 (1.6x10^11 vp)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
OPSCC, Oropharyngeal Squamous Cell Carcinoma (SCC)
Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma
HPV-associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a type of cancer that affects parts of the throat, like the tonsils and the base of the tongue.
- Conditions
- OPSCC, Oropharyngeal Squamous Cell Carcinoma (SCC), HPV Associated Cancers
- Trial name
- NCT06759155
- Testing
- de-intensified radiation
- Volunteers
- 20 people
- Sponsor
- University of Vermont Medical Center
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)
A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC
A prospective collection of 35 cases was conducted at Zhujiang Hospital of Southern Medical University. Patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous…
- Trial name
- NCT07133958
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhujiang Hospital
Oropharynx Cancer, Oropharynx Cancer, Metastatic
Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?
This study investigates if longitudinal analyses of cell-free HPV-DNA in blood samples can be utilized to detect recurrence in patients diagnosed and treated for HPV-positive oropharyngeal squamous cell carcinoma.
- Conditions
- Oropharynx Cancer, Oropharynx Cancer, Metastatic, Oropharynx Cancer, Recurrent, Oropharyngeal Carcinoma
- Trial name
- NCT06592716
- Testing
- Liquid biopsy
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Oropharyngeal Cancer
PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC
More and more studies have shown that the efficacy and prognosis of HPV （Human papillomavirus）-positive oropharyngeal cancer (OPC) patients are better than those of others.
- Trial name
- NCT06156891
- Testing
- Toxicities reduced treatment, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
HPV-positive Oropharyngeal Squamous Cell Carcinoma
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with transoral robotic surgery…
- Trial name
- NCT05419089
- Testing
- Robotic surgery
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV-associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Phase 2/3 Randomized Study of Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+…
- Trial name
- HexAgon-HN (NCT06295731)
- Testing
- INBRX-106, Pembrolizumab
- Where
- 89 sites in United States, Australia and 11 more
- Volunteers
- 450 people
- Sponsor
- Inhibrx Biosciences, Inc
HNSCC, OSCC
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
To investigate the neoadjuvant chemoimmunotherapy regimen of Ivonescimab combined with chemotherapy (Paclitaxel plus Cisplatin/Carboplatin) for the treatment of locally advanced resectable oral squamous cell carcinoma and…
- Conditions
- HNSCC, OSCC, OPSCC, Ivonescimab
- Trial name
- NCT07686575
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Zhujiang Hospital
Oropharyngeal Squamous Cell Carcinoma
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Pembrolizumab and nivolumab (with or without chemotherapy) are used to treat head and neck cancer. The middle part of the throat (oropharynx) is a common location for head and neck cancer.
- Trial name
- NCT06771674
- Testing
- Pembrolizumab, Nivolumab
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Hookipa Biotech GmbH
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
This clinical trial will evaluate a new combination of treatments for Oropharyngeal Squamous Cell cancers (OPSCC), and compare it to the current standard of care (concurrent, platinum-based chemoradiotherapy).
- Trial name
- NCT03715946
- Testing
- Nivolumab Injection, Radiotherapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Robert L. Ferris, MD, PhD
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC
To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for…
- Trial name
- NCT07844551
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab, Cisplatin
- Volunteers
- 40 people
- Sponsor
- Huashan Hospital
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma
This study will evaluate whether adding rimegepant to standard neoadjuvant chemoimmunotherapy can improve treatment response in patients with primary or recurrent oral or oropharyngeal squamous cell carcinoma who are planned to…
- Trial name
- NCT07812467
- Testing
- Rimegepant, Tislelizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma
Validity of Viome's Oral/throat Cancer Test
A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S.
- Conditions
- Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
- Trial name
- NCT06174428
- Testing
- Oral/Throat cancer test
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Viome
Oropharynx Cancer, Stage I
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
This phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable).
- Trial name
- NCT06254911
- Testing
- Atezolizumab, Transoral Surgery with cervical lymphadenctomy (neck dissection), Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Head and Neck Cancer, Squamous Cell Cancer
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
This study seeks to develop a new induction chemotherapy regimen which is a combination of two pill drugs taken by mouth and two drugs given by vein.
- Trial name
- NCT01721525
- Testing
- Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Trial name
- NCT05232851
- Testing
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
The goal of this clinical research study is to learn if utomilumab, when given with ISA101b, is able to shrink or slow the growth of tumors in patients with incurable HPV+ oropharyngeal squamous cell carcinoma.
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Trial name
- NCT03258008
- Testing
- Utomilumab, ISA101b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have very good outcomes. Patients' treatment responses depend more on their individual cancer characteristics and personal risk factors than on the…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Carcinoma
- Trial name
- SAVED (NCT07418034)
- Testing
- Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease
- Volunteers
- 132 people
- Sponsor
- University of Maryland, Baltimore